RNS Number : 9117A
Assura PLC
30 August 2024
 

30 August 2024

Assura plc

Total Voting Rights

In conformity with the FCA's Disclosure Guidance and Transparency Rules DTR 5.6.1 we hereby notify that the company's issued share capital consists of:

Issued shares and voting rights
3,236,951,244 ordinary shares of 10 pence each ("Shares")

The above figure of 3,236,951,244 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, shares of Assura plc under the FCA's Disclosure and Transparency Rules. No shares are held in treasury.

- Ends -

 

For more information, please contact:

 

Assura plc

 

Tel: 0161 515 2043

David Purcell, Investor Relations Director

 

Email: Investor@assura.co.uk

FGS Global

Gordon Simpson

Tel: 0207 251 3801

Email: Assura@fgsglobal.com

 

Notes to Editors

Assura plc is the UK's leading specialist healthcare property investor and developer. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.

At Assura we BUILD for health and as the first FTSE 250 certified B Corp we are committed to keeping ESG at the heart of our strategy, creating Healthy Environments (E) and Healthy Communities (S) and maintaining a Healthy Business (G).

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association
Assura plc LEI code: 21380026T19N2Y52XF72

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAPPNFEKLEEA